{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"035-029-449-461-237","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"035-029-449-461-237"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8819,"type":"PATENT","title":"Yale University","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":8278,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8206,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search applicants and owners = \"Yale univ\", \"Univ Yale\", \"Yale University\", \"University Yale\", \"Univ Yal*\", \"Yal* Univ*\", \"Yale Entrepreneurial Institute\".
Select more for logical variants
Add to collection
Select all the results in the collection and expand by simple family
Add to collection
Total patents: 7360
Search Applicants and Owners separately: uni* iowa
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 3686
Search applicants and owners = \"Yale univ\", \"Univ Yale\", \"Yale University\", \"University Yale\", \"Univ Yal*\", \"Yal* Univ*\", \"Yale Entrepreneurial Institute\".
Select more for logical variants
Add to collection
Select all the results in the collection and expand by simple family
Add to collection
Total patents: 7360
Search Applicants and Owners separately: uni* iowa
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 3686
wherein the biodegradable polymeric microparticles comprise a biodegradable polymer and between one and 50 weight percent of the water-soluble active agent dispersed therein,\n
wherein the hydrophilicity of the polymer forming the microparticles corresponds to the hydrophilicity of the active agent to be released, the hydrophilicity and charge of the polymer are selected to optimize percent loading of the active agent, and the molecular weight and monomer composition result in release of an effective amount of the active agent over a period of time of at least 60 days, when administered subconjunctivally, equivalent to administration of the active agent via the same route of administration in the absence of microparticles."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 1, wherein the microparticles are formed from one or more polymers selected from the group consisting of poly(lactic-co-glycolic) acid (PLGA)and a blend of PLGA and polylactic acid (PLA)."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 1, wherein the one or more water-soluble active agents are selected from the group consisting of selective or non-selective beta-adrenergic receptor blockers that lower intraocular pressure, antibiotics, steroids, growth factors, chemotherapeutic agents, and combinations thereof."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 3, wherein the selective or non-selective beta-adrenergic receptor blockers that lower intraocular pressure is selected from the group consisting of timolol, betaxolol, levobunolol, carteolol, metipranolol, and combinations thereof."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 3, wherein the antibiotic is selected from the group consisting of fluoroquinolone antibiotics, such as ofloxacin, levofloxacin, moxifloxacin, and gatifloxacin; aminoglycosides, such as streptomycin, kanamycin, aminodeoxykanamycin, kasugamycin, gentamicin, neomycin, tobramycin, netilmicin, and paromomycin; diaminopyrimidines, such as trimethoprim, and combinations thereof."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 3, wherein the growth factor is selected from the group consisting of NT-4, NT-3, brain derived neurotrophic factor (BDNF), and combinations thereof."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 3, wherein the steroid is selected from the group consisting of dexamethasone, hydroxydione, minaxolone, ORG 20599, ORG 21465, and combinations thereof."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 4, wherein the one or more active agents is timolol or a pharmaceutically acceptable salt thereof."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 1, wherein the percent loading of active agent is between 5 and 30 weight percent."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 1, wherein the polymer is PLGA having a molecular weight in the range from about 10 kD to about 80 kD."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 1 wherein the period of release is 90 days or greater in vivo."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 1 wherein the polymer comprises a plurality of carboxyl groups."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 12 wherein the polymer is PLGA."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 1, wherein the composition further comprises one or more pharmaceutically acceptable excipients."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["A method for administering one or more water-soluble active agents, comprising administering to the eye a biodegradable microparticulate pharmaceutical composition for delivery of the water-soluble active agent,\n
wherein the biodegradable polymeric microparticles comprise a biodegradable polymer and between one and 50 weight percent of the water-soluble active agent dispersed therein,\n
wherein the hydrophilicity of the polymer forming the microparticles corresponds to the hydrophilicity of the active agent to be released, the hydrophilicity and charge of the polymer are selected to optimize percent loading of the active agent, and the molecular weight and monomer composition result in release of an effective amount of the active agent over a period of time of at least 60 days, when administered subconjunctivally, equivalent to administration of the active agent via the same route of administration in the absence of microparticles."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 15, comprising administering the microparticles to the eye subconjunctivally."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 15, wherein the microparticles are formed from poly(lactic-co-glycolic) acid (PLGA) or a blend of PLGA and polylactic acid (PLA)."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 15, wherein the one or more water-soluble active agents are selected from the group consisting of selective or non-selective beta-adrenergic receptor blockers that lower intraocular pressure, antibiotics, steroids, growth factors, chemotherapeutic agents, and combinations thereof."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 18, wherein the selective or non-selective beta-adrenergic receptor blocker that lowers intraocular pressures is selected from the group consisting of timolol, betaxolol, levobunolol, carteolol, metipranolol, and combinations thereof."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 18, wherein the antibiotic is selected from the group consisting of fluoroquinolone antibiotics, such as ofloxacin, levofloxacin, moxifloxacin, and gatifloxacin; aminoglycosides, such as streptomycin, kanamycin, aminodeoxykanamycin, kasugamycin, gentamicin, neomycin, tobramycin, netilmicin, and paromomycin; diaminopyrimidines, such as trimethoprim, and combinations thereof."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 18, wherein the growth factor is selected from the group consisting of NT-4, NT-3, brain derived neurotrophic factor (BDNF), and combinations thereof."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 18, wherein the steroid is selected from the group consisting of dexamethasone, hydroxydione, minaxolone, ORG 20599, ORG 21465, and combinations thereof."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 19, wherein the one or more active agents is timolol or a pharmaceutically acceptable salt thereof."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 15, wherein the polymer is carboxylated PLGA and the percent loading of drug is from 5 to 30% by weight."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 24, wherein the polymer is a PLGA with a molecular weight from about 10 kD to about 80 kD."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 15, comprising administering the composition by injection."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 26, comprising administering the composition subconjunctivally."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["A kit comprising the compositions of claim 1."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["The kit of claim 28, wherein the kit further comprises instructions for preparing and/or administering the composition, optionally comprising a needle and syringe for administering the composition."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["The kit of claim 28, wherein the microparticles and the carrier are stored in the same container or in separate containers."],"number":30,"annotation":false,"title":false,"claim":true},{"lines":["The kit of claim 30, wherein the container is selected from the group consisting of sterile vials, jars, sealed ampules, and combinations thereof."],"number":31,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}